CLSA: Raises Shanghai Fosun Pharmaceutical (02196) H-share target price by 1.9% to HK$27.1, maintains "Outperform" rating

CLSA issued a research report stating that it has raised the H-share target price of Shanghai Fosun Pharmaceutical (02196, 600196.SH) by 1.9%, from HK$26.6 to HK$27.1, and also raised its A-share target price, maintaining an "Outperform" rating. The bank said that Shanghai Fosun Pharmaceutical's third-quarter results were broadly in line with expectations, with steady sales growth of innovative products driving margin improvement. Looking ahead, the global Phase III clinical trial results of AR1001 for the treatment of Alzheimer's disease will become a key near-term catalyst. In addition, the continued commercialization progress of serplulimab in China, as well as regulatory progress in the United States and Japan, also provide the company with additional growth options.